Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Leuk Res. 2010 Sep 15;35(3):310–316. doi: 10.1016/j.leukres.2010.06.010

Table 1.

Patient characteristics and treatment data.

Patient number Age Sex AML subtype Cytogenetics Treatment Aplastic (day 14) Reinduction Complete remission (4–6 weeks) Clinical response
1 67 M M4 46 X, Y Ida + Ara-C Yes No Yes CR
2 47 F M2 46 X, X Ida + Ara-C Yes No No RD
3 55 M MLD 46 X, Y Ida + Ara-C Yes No Yes CR
4 47 M M7 Complex Ida + Ara-C No Yes Yes CR
5 20 M M1 46 X, Y Ida + Ara-C No Yes No RD
6 59 M MLD 46 X, Y Ida + Ara-C Yes No Yes CR
7 70 F M4 46 X, X −7, + 21 MY-FLAI No Noa No RD
8 19 M MLD 46 X, Y Ida + Ara-C No Yes Yes CR

MLD: multilineage dysplasia, Ida + Ara-C: idarubicin + cytarabine, MY-FLAI: fludarabine, idarubicin, cytarabine, gemtuzumab ozogamicin.

a

Patient 7 did not receive a second induction due to resistant disease (49% blasts in a hypercellular marrow) found on the day 14 bone marrow biopsy and other comorbidities.